Intermountain Precision Genomics grows its gene panel for cancer treatments
Intermountain Precision Genomics, a service of Intermountain Healthcare, has expanded its ICG100 to include a total of 162 genes.
The ICG100 Comprehensive Gene Panel tests genes often associated with cancer. The test is approved for late stage cancer patients who have failed a traditional treatment method.
“The expansion of the ICG100 Comprehensive Gene Panel allows us to advance the capabilities of treating acute leukemia and Myelodysplastic Syndrome, Intermountain Precision Genomics Core Laboratory Manager David Loughmiller said in a statement.
The system also advanced its ability to reduce the amount of DNA needed to perform the test, Loughmiller added. “Lower input allows us to accept more samples from smaller biopsies. As we hone our research competencies and data pipelines in the laboratory, we are better able to impact lives and serve more patients.”
The ICG100 process includes an in-depth analysis of gene sequencing. The test identifies mutations at a genomic level, and then targets existing mutations with a personalized therapy.
Intermountain Healthcare oncologists have direct access to the Intermountain Precision Genomics Core Laboratory through their provider login. Outside of Intermountain Healthcare, physicians can visit precisioncancer.org to create an online ordering portal.
Twitter: @Bernie_HITN
Email the writer: bernie.monegain@himssmedia.com
